Merck Looking For FDA Green Light For Englonsia Beyond First RSV Season

February 23, 2026

FDA accelerated approval decision on Alzheimer’s drug likely to come soon

January 6, 2023

Lilly plans to construct a $2.5 billion manufacturing facility in Germany

November 21, 2023

Must Read

Top 10 Operational Bottlenecks Slowing AI Adoption in Pharma

June 7, 2026

Lilly Licenses Hanmi’s Phase 2 GLP-2 Drug for Short Bowel Syndrome in Deal Worth Up to $1.26 Billion

June 7, 2026

AZ Reports Phase 3 Emerald-3 Progression-Free Survival Benefit for Imfinzi and Imjudo in Unresectable HCC

June 7, 2026

About Us

Life Sciences Voice is the leading resource for life sciences executives to get crucial insights, explore the latest innovations, and learn about industry trends. Life Sciences Voice provides the community with thought-provoking commentary in multiple formats covering a range of issues from drug discovery to commercial success.

Early research shows that Lilly’s Verve strategy is successful in lowering cholesterol

Kailera Details Nasdaq IPO Plans to Raise Up to $528.5 Million for Obesity Drug Development

Avalyn Files for IPO to Fund Late-Stage Development of Inhaled Lung Disease Therapies

Merck Pays $20 Million Upfront to Access Quotient’s Somatic Genomics Platform for IBD Research

AZ Reports Phase 3 Emerald-3 Progression-Free Survival Benefit for Imfinzi and Imjudo in Unresectable HCC

Revolution & Summit Witness Share Surge As Experimental Cancer Drugs Perform in Trials

Phase 3 Trial Shows Obefazimod Achieves Clinical Remission in Ulcerative Colitis Patients

After a phase 2 failure, Biogen ends Parkinson’s prospects with Denali

Lilly Licenses Hanmi’s Phase 2 GLP-2 Drug for Short Bowel Syndrome in Deal Worth Up to $1.26 Billion

Subtle Medical Gets $33M Series C Funding, Appoints New CEO

For CAR-T biotech InnocsAI, struggling Liminatus pays $320 million in equity

Chugai and Gero Partner to Develop Antibodies for Age-Related Diseases Using AI

J&J MedTech presents the first Ottava surgical robot clinical cases

Wisp Launches Weight Care Vertical for Women with Hormonal Imbalances

PicnicHealth Launches New Service Bringing Observational Clinical Trials to the Virtual Realm

Top 10 Operational Bottlenecks Slowing AI Adoption in Pharma

Top 10 Reasons Omnichannel Engagement Still Falls Short in Healthcare

AI in Medical Affairs: How Pharma Is Becoming a Real-Time Scientific Intelligence System

Are Pharmaceutical Companies Moving Too Fast With AI Adoption?

Tag: kyowa kirin pharma asset sales

Kyowa Kirin considering asset sales of $1B as focus shifts to PI3K inhibitor advancement

Editor Picks

Merck Looking For FDA Green Light For Englonsia Beyond First RSV Season

FDA accelerated approval decision on Alzheimer’s drug likely to come soon

Lilly plans to construct a $2.5 billion manufacturing facility in Germany

Must Read

Top 10 Operational Bottlenecks Slowing AI Adoption in Pharma

Lilly Licenses Hanmi’s Phase 2 GLP-2 Drug for Short Bowel Syndrome in Deal Worth Up to $1.26 Billion

AZ Reports Phase 3 Emerald-3 Progression-Free Survival Benefit for Imfinzi and Imjudo in Unresectable HCC

Hot Topics

About Us

Follow Us